09.13.13
Robert B. Hance will take over the role of CEO at Galway, Ireland-based Creganna-Tactx on Sept. 30. He replaces Helen Ryan, who has held the position since 2005.
Hance has extensive experience in the medical device sector with more than 23 years at Abbott Laboratories, most recently as president of Abbott Vascular. Over a four-year period at Abbott Vascular, Hance led a 9,000-person organization through a period of significant sales growth from $1.7 billion in 2007 to $3.3 billion in 2011 by leveraging the company in the drug- eluting stent market.
Prior to joining Abbott in 1989, Hance was an associate fellow at Harvard Business School and a product development engineer at Procter & Gamble. He earned a bachelor’s degree in chemical engineering from the Massachusetts Institute of Technology and a master’s degree in Business Administration from Harvard Business School.
Scott R. Ward, chairman of Creganna-Tactx, said the company’s board unanimously selected Hance based on his extensive experience within the medical device industry.
“Hance has an outstanding track record as a leader who delivers high quality innovative medical device products to achieve exceptional business growth,” Ward said in prepared remarks. “I would like to take this opportunity to thank Helen for the leadership and strong customer focus she has shown in her role as chief executive. Thanks to Helen’s commitment and vision, Creganna-Tactx Medical has a strong and solid future as a leader in delivering medical technology solutions.”
Hance said that he looked forward to serving Creganna-Tactx’s customers, while Ryan congratulated him on his appointment and wished him success. According to a company spokesperson, Ryan will continue on the board of Creganna-Tactx Medical in a non-executive director role.
Creganna-Tactx specializes in the design and manufacture of minimally and less invasive delivery and access devices for a range of therapies.
Hance has extensive experience in the medical device sector with more than 23 years at Abbott Laboratories, most recently as president of Abbott Vascular. Over a four-year period at Abbott Vascular, Hance led a 9,000-person organization through a period of significant sales growth from $1.7 billion in 2007 to $3.3 billion in 2011 by leveraging the company in the drug- eluting stent market.
Prior to joining Abbott in 1989, Hance was an associate fellow at Harvard Business School and a product development engineer at Procter & Gamble. He earned a bachelor’s degree in chemical engineering from the Massachusetts Institute of Technology and a master’s degree in Business Administration from Harvard Business School.
Scott R. Ward, chairman of Creganna-Tactx, said the company’s board unanimously selected Hance based on his extensive experience within the medical device industry.
“Hance has an outstanding track record as a leader who delivers high quality innovative medical device products to achieve exceptional business growth,” Ward said in prepared remarks. “I would like to take this opportunity to thank Helen for the leadership and strong customer focus she has shown in her role as chief executive. Thanks to Helen’s commitment and vision, Creganna-Tactx Medical has a strong and solid future as a leader in delivering medical technology solutions.”
Hance said that he looked forward to serving Creganna-Tactx’s customers, while Ryan congratulated him on his appointment and wished him success. According to a company spokesperson, Ryan will continue on the board of Creganna-Tactx Medical in a non-executive director role.
Creganna-Tactx specializes in the design and manufacture of minimally and less invasive delivery and access devices for a range of therapies.